Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results